• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Albinterferon-alpha 2b: a new treatment option for hepatitis C.
【24h】

Albinterferon-alpha 2b: a new treatment option for hepatitis C.

机译：Albinterferon-alpha 2b：丙型肝炎的新治疗选择。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IMPORTANCE OF THE FIELD: HCV infection affects 180 million people worldwide. Standard therapy combines weekly injections of pegIFN and daily ribavirin (RBV). Albinterferon (albIFN)-alpha2b is the most advanced in the development of an IFN-based compound. AREAS COVERED IN THIS REVIEW: The rationale for albIFN-alpha2b is to combine IFN-alpha antiviral activity with prolonged presence of human serum albumin in human blood. Initial experimental studies on albIFN-alpha2b were published in 2002. This review provides results of preclinical and subsequent clinical trials. Results of two Phase III clinical trials were presented in 2009 and will be published shortly. WHAT THE READER WILL GAIN: This review discusses the current status of knowledge on the efficacy and safety of albIFN-alpha2b. Phase III clinical trials demonstrated comparable efficacy of albIFN-alpha2b given every 2 weeks to weekly pegIFN-alpha2a, both in combination with RBV. However, the most promising seems to be every 4 weeks dosage. TAKE HOME MESSAGE: Treatment with albIFN-alpha2b combined with RBV can provide comparable efficacy with the current standard of care medication with a reduced number of injections. Lower frequency of some adverse events and improved quality of life can be expected in patients receiving albIFN-alpha2b every 4 weeks.
机译：领域的重要性：HCV感染影响了全世界1.8亿人。标准疗法将每周一次的pegIFN和每日利巴韦林（RBV）注射。 Albinterferon（albIFN）-alpha2b是基于IFN的化合物开发中最先进的。综述中涉及的领域：albIFN-α2b的基本原理是将IFN-α抗病毒活性与人类血液中白蛋白的存在时间延长相结合。 2002年发表了有关albIFN-alpha2b的初步实验研究。该综述提供了临床前和后续临床试验的结果。 2009年提出了两项​​III期临床试验的结果，并将很快发表。读者的收获：这篇评论讨论了关于albIFN-α2b的功效和安全性的知识的现状。 III期临床试验表明，与RBV联合使用，每2周给予albIFN-α2b的效果与每周一次的pegIFN-alpha2a相当。但是，最有前途的似乎是每4周服用一次。进行家庭消息：将albIFN-α2b与RBV联合治疗可以通过减少注射次数提供与当前标准护理药物相当的疗效。每4周接受albIFN-alpha2b的患者发生某些不良事件的频率会降低，生活质量也会得到改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号